MAPT and Alzheimer disease: This accumulating evidence suggests that TREM2 and other innate immune pathways may play detrimental roles in early stages of human AD, when Aβ predominates (estimated to be as many as 10–20 years prior to clinical onset), but beneficial roles at later stages of human AD, when tau pathology develops, that has direct implications for the development of therapeutic strategies targeting these pathways.